AGP
PCVX icon

Artia Global Partners’s Vaxcyte PCVX Stock Holding History

Artia Global Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-162,255
Closed -$13.3M – 45
2024
Q4 		$13.3M Buy
162,255
+86,000
+113% +$8.54M 4.75% 8
2024
Q3 		$8.71M Hold
76,255
– – 2.38% 10
2024
Q2 		$5.76M Hold
76,255
– – 1.11% 16
2024
Q1 		$5.21M Buy
76,255
+37,700
+98% +$2.61M 1.05% 16
2023
Q4 		$2.42M Hold
38,555
– – 0.7% 18
2023
Q3 		$1.97M Hold
38,555
– – 0.82% 18
2023
Q2 		$1.93M Buy
38,555
+15,796
+69% +$749K 0.66% 26
2023
Q1 		$853K Buy
+22,759
New +$965K 0.32% 30

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Artia Global Partners's PCVX Position: Q1 2025 in Review

Artia Global Partners sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 162,255 shares — an estimated $13.3M sold.

Artia Global Partners first reported a position in PCVX in Q1 2023 and held it in 8 quarters. The position peaked at $13.3M in Q4 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Artia Global Partners reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
  • Artia Global Partners sold 162,255 Vaxcyte shares in Q1 2025, an estimated $13.3M.
  • Artia Global Partners first reported a position in Vaxcyte in Q1 2023 and held it in 8 quarters.
  • Artia Global Partners's Vaxcyte position peaked at $13.3M in Q4 2024.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Artia Global Partners's 13F filing for Q1 2025, filed 15 May 2025.